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Abstract
Background:  Combined chemoradiotherapy (CRT) is the treatment of choice for stage III
NSCLC. Gemcitabine (G) is a novel deoxycitidine analogue that has been proven to be a potent
radiosensitizer. Twenty-two consecutive patients were treated with concurrent CRT to
demonstrate the tolerability and efficacy of low dose G given weekly as radiosensitizer in stage III
NSCLC.
Methods: Patients with KPS ≥ 70, adequate bone marrow reserve, with no prior radiotherapy (RT)
and surgery were included. Eighteen patients had received prior induction chemotherapy (CT). G
(75 mg/m2/week) was infused over 1 hour for 6 weeks. Thoracic RT was given two hours later over
6 weeks at 1.8 Gy/day fractions (total dose of 61.2 Gy). Pulmonary toxicity was evaluated with
computed tomography scans in 6 weeks.
Results: Median age was 60 years (range, 48–75), median follow-up was 15 months (range, 2–40).
Sixty-eight percent of patients were male and median KPS score was 90. Conformal 3D-RT
planning was used in 64% of patients. G was given for a median of 5 weeks (range 1–9). Twelve
patients (54.6%) received all planned CT. G was stopped because of intolerance in 6 and death in
2 patients. Seven patients (31.8%) had radiation pneumonitis. Twenty patients were evaluated for
overall response, 1 patient (4.5%) had clinical CR, 81.8% had PR while 9.5% had SD. Median overall
survival (OS) was 14 ± 5 months (95% CI 3–25). One- and 2-year OS rates were 55% and 38%.
Sixteen patients died of disease-related events (6 with progression of primary tumor, 8 due to
metastatic disease), 2 patients died of other causes. One- and 2-year progression-free survival and
local control rates were 56%, 27% and 79%, 51%, respectively.
Conclusion: G might be used as radiosensitizer for patients with stage III NSCLC who could not
receive full doses CT with concurrent RT.
Background
Lung cancer is the leading cause of cancer related deaths
all around the world. About 80% of all lung cancer
patients are non-small cell lung cancer (NSCLC) and 20–
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30% of these patients present with locally advanced dis-
ease. Although 1-year survival rate of patients with local
disease is more than 70%, this rate is about 40% for
patients with stage III disease [1]. Chemoradiotherapy
(CRT) is considered the gold standard treatment of these
patients after significant survival advantage and increase
in local control had been shown by 3 meta-analyses [2-4].
Sequential versus concurrent CRT has been further inves-
tigated and concurrent CRT has been found to be superior
[5-7]. Despite advances in treatment modalities overall 5-
year survival rate for locally advanced NSCLC remains less
than 15% [8].
Gemcitabine (G) is a deoxycytidine analogue that demon-
strated activity in NSCLC as single agent and in combina-
tion also has been proven to be a potent radiosensitizer.
Mechanism of radiosensitizing activity of G is not well
understood. Possible mechanisms that have been shown
in preclinical studies are reduction of apoptotic threshold
for radiation due to intracellular dATP pool depletion
with simultaneous redistribution of cells into the S phase
[9]. As a result of these factors DNA damage caused by
radiation cannot be properly repaired, apoptosis was
induced and cell death increased. The average enhance-
ment ratio of G is ≥ 1.5 and sensitization persists for at
least 72 hours [10]. Preclinical data supports that more
frequent G dosing schedule with radiation could yield
local control advantages in the setting of a clinical trial
[11].
In this study it is aimed to demonstrate the efficacy and
tolerability of low dose G given weekly as radiosensitizer
in stage III NSCLC patients.
Methods
Consecutive patients between the ages 18–75 years with
histological or cytological confirmed stage III NSCLC who
had Karnofsky Performance Status (KPS) ≥ 70 in Medical
and Radiation Oncology Clinics of Marmara University
between December 1999 and July 2002 were considered
for this study. Other patient selection criteria were white
blood cell count ≥ 3000/mm3, hemoglobin level ≥ 10 gr/
dl, platelet count ≥ 100000/mm3, no prior RT or lung
resection accept open lung biopsy or mediastinoscopy for
diagnostic purposes. All combinations and cycles of
induction CT prior to planned concurrent CRT were eligi-
ble as the ones who did not receive any induction CT. All
patients started CRT within 1 month after completion of
induction CT. There was not a limitation to the lung vol-
ume planned to be irradiated.
The overall dose of RT was 60–61.2 Gy administered over
6 weeks with daily fractions of 2 Gy administered for 5
days each week. Planning computed tomography scan
(CTS) was performed for each patient in supine position.
The planning target volume (PTV) consisted of radiologi-
cal visible primary tumor with a margin of 2 cm in each
diameter. Elective nodal irradiation field included the PTV
for the first 6 patients. After 6 patients the treatment plan-
ning and volume was amended to multiple field arrange-
ments with custom blocking to all fields and involved
hilar and mediastinal lymph nodes. Irradiation was
administered with megavoltage photons of at least 6 MV.
The dose of 60 Gy was specified at the isocenter of the cen-
tral axis and was corrected for pulmonary heterogeneity.
The spinal cord was not allowed to receive RT more than
45 Gy.
G (75 mg/m2/week) was infused each Monday by i.v.
route over 1 hour in 500 cc of 0.9% normal saline for 6
weeks. RT was administered 2 hours after the G infusion.
5-HT antagonists were given 30 minutes prior to G
infusion.
Patients were followed weekly with routine physical
examination and complete blood count (CBC). Toxicity
was graded according to the National Cancer Institute
Common Toxicity Criteria (CTC), version 2.0 [12]. If the
patient had WBC ≤ 2500/mm3, platelets ≤ 50000/mm3 or
grade 3 or 4 hematological toxicity, G was not adminis-
tered that week. G was stopped if CBC was as low as men-
tioned above for 2 consecutive weeks or grade ≥ 3 non-
hematological toxicities were seen during the treatment
period.
Pulmonary toxicity was evaluated with CTS of the thorax
6 weeks after the completion of RT. Patients having
ground glass appearance or alveolar consolidation on CTS
were started on corticosteroids (40 mg of fluocortolon
daily, which is the standard treatment protocol of the cen-
tre) for 2–4 weeks even if they were asymptomatic.
Responses were routinely evaluated in 3 months. Stand-
ard World Health Organization (WHO) criteria were used
to determine response [13]. Tumor volume at the begin-
ning of CRT was compared to the volume at the end of
this treatment and this difference was used to calculate the
response rate. Survival rates were calculated by using the
Kaplan-Meier method.
Results
Total of 22 consecutive patients were treated with this
treatment protocol. Patient characteristics are given in
Table 1. Median age was 60 years (range, 48–75) and
68.2% were male. Median KPS score was 90 (range, 70–
100). This group had a median 43 pack-years smoking
history (range, 0–90). Fifty percent of the patients had
stage IIIA disease. Twelve patients (54.5%) had squamous
cell histology. Eighteen patients had induction CT and
median number of cycles was 3 (range, 2–8). One patient
received 8 cycles, 3 patients received 6 cycles, 3 patientsBMC Cancer 2005, 5:71 http://www.biomedcentral.com/1471-2407/5/71
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received 4 cycles of induction CT. After induction CT, 9
patients (40.9%) had partial response (PR), 5 (22.7%)
had stable disease (SD) and 4 (18.2%) had progressive
disease (PD). The patient who had 8 cycles of induction
CT received 4 cycles of two different CT regimens and had
PD after both. Two of the other three patients who
received 6 cycles of induction CT had SD and 1 had PR.
Table 1: Patient characteristics
Characteristics Number (n) Percentage (%)
Gender
Male 15 68.2
Female 7 31.8
Stage
IIIA 11 50
IIIB 11 50
KPS
70 4 18.2
80 5 22.7
90 12 54.5
100 1 4.5
Histology
Adenocarcinoma 6 27.3
Squamous cell carcinoma 12 54.5
Adenosquamous cell carcinoma 1 4.5
Unclassified 3 13.6
ICT
Yes 18 81.8
No 4 18.2
ICT Regimens
PE 4 22.2
NP or NC 6 33.3
GP 3 16.7
INC 2 11.1
TC 2 11.1
INC + TC 1 5.6
Number of ICT Cycles
2–3 11 61.1
≥ 47 3 8 . 9
Response to ICT
PR 9 50
SD 5 27.8
PD 4 22.2
ICT: Induction Chemotherapy, PE: Cisplatin-Etoposide, NP: 
Vinorelbine-Cisplatin, NC: Vinorelbine-Carboplatin, GP: 
Gemcitabine-Cisplatin, INC: Ifosfamide-Navelbine-Carboplatin, TC: 
Paclitaxel-Carboplatin, PR: Partial Response, SD: Stable Disease, PD: 
Progressive Disease
Table 2: Treatment characteristics of the patients
Variable Number (n) Percentage (%)
RT Planning
Conventional 8 36.4
Conformal 14 63.6
RT Dose/Fraction
1.8 Gy 13 59.1
2 Gy 9 40.9
Number of RT Treatment Weeks
41 4 . 5
5–7 16 72.7
≥ 8 5 22.7
Number of G Treatment Weeks
≤ 4 7 31.8
5–7 13 59.1
≥ 82 9 . 1
RT: Radiotherapy, G: Gemcitabine
Table 3: Non-hematological and hematological toxicities for 
CRT and responses
Variable Number (n) Percentage (%)
Pneumonia 7 31.8
Grade 1 4 18.2
Grade 2 2 9.1
Grade 5 1 4.5
Nausea/Vomiting 4 18.2
Grade 1 2 9.1
Grade 2 2 9.1
Esophagitis 16 72.8
Grade 1 8 36.4
Grade 2 4 18.2
Grade 3 4 18.2
Hematological toxicity 5 22.7
Grade 1 3 13.6
Grade 2 2 9.1
Response to CRT
Clinical CR 1 4.5
PR 18 81.8
SD 2 9.1
Unknown 1 4.5
CRT: Chemoradiotherapy, CR: Complete Response, PR: Partial 
Response, SD: Stable diseaseBMC Cancer 2005, 5:71 http://www.biomedcentral.com/1471-2407/5/71
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Conformal 3D-RT planning was used in 63.6% of the
patients. Median RT dose administered was 60 Gy (range,
32–66 Gy) with 1.8 Gy (range, 1.8–2 Gy) daily fraction in
a median of 46 days (range, 29–64 days) over 7 weeks
(range, 4–9 weeks). Elective nodal irradiation was given in
6 patients (27.3%). Rest of the patients (72.7%) received
RT only to tumor and involved hilar and mediastinal
lymph nodes (Table 2).
G was given for a median of 5 weeks (range, 1–9). Twelve
patients (54.6%) received all planned CT. G was stopped
in 8 patients, because of intolerance (grade 2–3 fatigue,
nausea, vomiting, esophagitis and low CBC for 2 consec-
utive weeks) in 6 and death during treatment in 2. One
patient who died of pneumonia had asymptomatic con-
gestive heart failure and 52.5 pack-years smoking history.
Another patient died with acute onset of loss of conscious-
ness, hypotension, breathing depression, and this was
considered to be secondary to cerebrovascular accident.
Both deaths were seen on the 5th week of treatment. In 2
patients G was held in the middle of the treatment for 1
week because of grade 2 hematological toxicity. Neutrope-
nia and anemia were the most significant toxicities
observed (Table 2 and 3). There were only 4 patients
(18.2%) who had acute grade 3 esophagitis, while no
other grade 3 acute toxicity was seen. These 3 patients had
recovered completely after completion of RT. Seven
patients (31.8 %) had radiation pneumonitis; four
(18.2%) of these had grade 1, two (9.1 %) had grade 2
and one patient had grade 5 (4.5%) (Table 3). One other
patient was not assessed because of new brain metastasis
was seen right after the completion of her CRT. All
patients with signs of radiation pneumonitis on their CTS
received corticosteroid treatment, according to our cent-
ers' protocol.
One patient (4.5%) had clinical CR, 18 (81.8%) had PR,
while 2 (9.5%) had SD after CRT. Two patients who had
PR were operated (1 had lobectomy, the other pneumon-
ectomy). Two other patients received adjuvant CT after
completion of CRT (Table 3).
Median follow-up was 15 months (range, 2–40 months).
Median overall survival (OS) was 14 months (Figure 1).
One- and 2-year OS rates were 54.5% and 37.5%. Sixteen
patients (72.7%) died, 6 (27.3%) with progression of
their primary NSCLC, 8 due to metastatic disease (brain
metastasis in 6, contralateral lung metastasis in 2), 1 with
pneumonia and another with cerebrovascular event.
Median disease free survival (DFS) was 14 months, while
1- and 2-year DFS rates were 55.5% and 26.5%, respec-
tively. Seven patients (31.8%) progressed locally, while 8
other (36.4%) had distant metastasis during follow-up
after CRT. Another patient had both local progression and
distant metastasis. Five of the patients with local progres-
sion had stage IIIB disease initially. First site of metastasis
seen in this group was brain in 4, contralateral lung in 3,
skin in 1 and neck in another patient. Local control was
achieved in 63.6% of the patients. One- and 2-year local
control rates were 78.6% and 51%, respectively (Table 4).
Discussion
For many years the mainstay of treatment for non-resect-
able NSCLC was RT alone. The results of several phase II
studies provided support for the addition of CT to RT and
a landmark trial was reported by Dillman et al in 1990
[14]. He demonstrated increased rates of three-year and
long-term survival [15]. Two large meta-analyses have
provided support for the benefit of CRT combinations
[3,4].
The initial phase I and II clinical experience in NSCLC had
demonstrated that weekly G (600–1000 mg/m2) with
concurrent standard thoracic RT was effective, but it had
significant toxicity (pulmonary fibrosis, esophagitis,
thrombocytopenia and neutropenia) [16-21]. Doses of G
used in these preliminary phase II studies were not
derived from well-planned phase I studies and were very
high. Also significant number of patients had dose
reductions or they missed doses during the treatment.
After these unclear results dose escalating trials of G as a
radiosensitizer with concurrent RT were started [22,23]. In
one of the first studies Gonzalez et al recommended that
G can be used at 300 mg/m2/week dose with 50 Gy of RT,
but the dose of RT was lower than standard in this trial
[16]. McMullen et al reported in their phase I/II trial
(CALGB 89805) that 70 mg/m2/week was the recom-
mended dose of G with 60–74 Gy RT [23]. Trodella et al
recommended weekly G dose of 350 mg/m2 for 5 weeks
concurrent with 50.4 Gy RT after their phase I trial [24].
Our rationale for evaluating weekly 75 mg/m2 dosing was
based upon a phase I study of Blackstock et al [22]. In that
study they suggested that thoracic RT and G given with a
dose of weekly 70 mg/m2 in two days appeared tolerable
in patients with advanced NSCLC. Although this was a
phase I study, overall response rate for 16 patients was
88% and median survival for all 17 patients was 16
months. Dose limiting toxicities were pulmonary (pneu-
monitis, pulmonary fibrosis), esophageal (esophagitis,
esophageal stricture, ulceration), and hematological (ane-
mia, thrombocytopenia) toxicities in this CALGB trial
[22]. They delivered almost all the planned G doses
(range, 7–12). Several preclinical [25-27] and clinical
[28,29] trials have also shown G to be an effective RT
enhancer, even when low doses are administered.
In this study the RT planning was changed from 2D con-
ventional to 3D conformal multiple fields planning after
the first 6 patients. G given concurrently with 3D-RT isBMC Cancer 2005, 5:71 http://www.biomedcentral.com/1471-2407/5/71
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much better tolerated than with 2D-RT and a reduction in
grade 3 esophagitis was seen, as it was reported by Zinner
et al [30]. The maximal tolerated dose of G given concur-
rently 7 weeks on row with RT as a radiosensitizer was 190
mg/m2/week with 3D planning while 125 mg/m2/week
could be administered with 2D-RT in that study. In our
study the differences in the rates of grade 3 or 4 esophag-
itis and pneumonia between the two treatment schedules
were not significant. This might be due to having small
number of patients in our study. We also changed elective
nodal irradiation to involved nodal irradiation after the
first 6 patients. Emami et al concluded in their analysis of
the RTOG data that elective irradiation of uninvolved
Overall survival plot for all patients Figure 1
Overall survival plot for all patients.
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Table 4: Overall survival, progression-free survival and local 
control data
Months ± SD (95% Confidence Interval)
Median OS 14 ± 5 (3–25)
Median PFS 14 ± 3 (8–20)
1-year (%) 2-year (%)
OS Rates 55 38
PFS Rates 56 27
Local Control Rates 79 51
OS: Overall survival, PFS: Progression-free survivalBMC Cancer 2005, 5:71 http://www.biomedcentral.com/1471-2407/5/71
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supraclavicular and mediastinal nodes may not be neces-
sary in the treatment of unresectable NSCLC [31].
Blackstock et al also reported that there appeared to be a
relationship between volume of lung irradiated, pre-treat-
ment pulmonary function and pulmonary fibrosis,
although the data was limited in their phase I trial [22].
Pre-treatment volumes of the tissue irradiated was not cal-
culated in our patient population, but they were much
larger than 2000 cm3 which was reported as a cut off in
inclusion criteria in the trial reported by Price et al. [28].
Therefore we favored to administer a much lower dose of
G then what was used in the above trial.
G and cisplatin have also been studied with concurrent
RT. Phase II data have been reported during the last years.
Vokes et al recommended 600 mg/m2/day, day 1 and 8 of
G and 80 mg/m2/day of cisplatin repeated every 21 days ×
2 courses during RT (66 Gy) and this was the dose used in
CALGB 9431 [32]. There was a marked increase in the tox-
icities of this schedule, especially in hematological toxici-
ties and esophagitis. Although this was a phase II study,
median survival was reported as 18.3 months which is 1–
2 months longer than other concurrent CRT studies. In
several randomized phase III trials comparing chemother-
apy (either sequential or concomitant) with RT alone, the
median survival was found between 8–18 months [3]. In
our study median survival was 14 months. Although the
survival data's extracted from phase II studies should not
be used for comparison, this survival difference between
our pilot study and other phase II data might be secondary
to using lower dose of G in our study, having 2 very early
deaths, lower dose of RT administered, not using cispla-
tin, treating patients with more tumor load or nature of
the disease. But the median survival in our study was sim-
ilar to the phase III data [3].
In our study there might be two reasons for the high inci-
dence of radiation pneumonitis. The first reason might be
the high number of cycles of induction CT. Three of the
four patients receiving 6 or more cycles of induction had
grade 1 or 2 pneumonitis. Although chemotherapeautic
agents were found to induce radiation pneumonitis either
alone or with radiation therapy in previous studies this
was not seen in our patients [33-35]. The other reason
might be the screening schedule of pneumonitis in our
centre. All of the patients were considered for radiation
pneumonitis during the first CTS examination for the
tumor response. The patients received corticosteroid ther-
apy for radiation pneumonitis according to the CTS
images but most of them were asymptomatic.
The patients could not receive all planned G dose concur-
rent with RT. Heavily pre-treated patients with induction
CT before CRT might have not tolerated weekly planned
G schedule. Eighteen of the patients had induction CT, the
median number of cycles were 3 and seven of the patients
received ≥ 4 cycles. The reasons for this were that patients
either progressed during induction CT and received sec-
ond line CT regimens or longer induction CT was their
physicians decision before referring them to our centre for
RT.
Conclusion
G might be used as radiosensitizer for patients with stage
III NSCLC who could not receive full doses CT with con-
current RT. In order to decrease the therapy associated tox-
icities smaller irradiation volumes used with 3D
conformal techniques might be better. We need prospec-
tive randomized trials with increased number of subjects
in order to figure out where this regimen exactly stands in
the standard treatment of this group of patients.
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